ITIH4: A New Potential Biomarker of “Toxin Syndrome” in Coronary Heart Disease Patient Identified with Proteomic Method
Table 4
Comparison of difference between before and after treatment in the two groups.
Mass (Da)
Ave ± StdDev (A__Q)
Ave ± StdDev (B__Q)
1329.42
−4.18 ± 5.02
0.4 ± 6.86
0.005918
1519.06
−7.1 ± 7.9
−2.47 ± 9.08
0.046435
2660.01
−82.12 ± 130.27
3.85 ± 184.48
0.047102
2881.04
4.86 ± 16.64
−11.62 ± 23.4
0.003442
3207.37
6.56 ± 21.34
−8.31 ± 19.09
0.008696
3277.49
14.13 ± 27.75
−9.87 ± 33.72
0.005087
3972.15
−8.69 ± 22.59
3.47 ± 15.5
0.02561
4279.95
−2.49 ± 14.27
8.32 ± 19.41
0.020196
5066.25
−0.43 ± 10.97
6.23 ± 13.8
0.049446
5807.76
18.84 ± 34.89
−2.2 ± 36.2
0.031283
5822.51
9.44 ± 16.49
−7.75 ± 32.03
0.013558
6088.68
8 ± 28.11
−8.21 ± 25.58
0.029233
Note: paired sample -test was used, 2-tailed, and was considered significant; Ave: peak area/intensity average; StdDev: standard deviation of the peak area/intensity average; “A_H − A_Q”: subtraction between after and before treatment in group A; “B_H − B_Q”: subtraction between after and before treatment in group B; overstriking mass: unique to “Toxin.”
